HIGH-VOLUME · SEX-BALANCED
secukinumab Side Effects
secukinumab (also sold as Cosentyx) is HIGH-VOLUME in this FAERS book #41 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 62% of sex-coded reports are female (90,501 F / 55,361 M).
Data updated 2026-05-15
- 157,236
- FAERS reports
FAERS voluntary reports, 2012 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
secukinumab reporting skew - 62% of sex-coded reports are female (90,501 F / 55,361 M). Volume band HIGH-VOLUME #41 of 524 by FAERS report count; caseload MEGA-CASE.
High-report extract for secukinumab (Cosentyx): 157,236 FAERS rows (2012-2025). Top named reactions: PSORIASIS, PAIN, ARTHRALGIA. Outcome stamps DEATH-MARKED · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2012–2025). Stamps MEGA-CASE · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
PSORIASIS leads 22,567 of 157,236 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (30,760 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 7,752 reports (4.9% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 2,376 |
| SYSTEMIC LUPUS ERYTHEMATOSUS | 2,110 |
| PSORIATIC ARTHROPATHY | 2,092 |
| TYPE 2 DIABETES MELLITUS | 2,053 |
| SYNOVITIS | 2,047 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2,039 |
| HYPOAESTHESIA | 2,035 |
| GLOSSODYNIA | 2,032 |
| RASH | 2,026 |
| RHEUMATOID ARTHRITIS | 2,015 |
| FIBROMYALGIA | 1,992 |
| SWELLING | 1,990 |
| WOUND | 1,985 |
| FATIGUE | 1,984 |
| HAND DEFORMITY | 1,981 |
| JOINT SWELLING | 1,961 |
| FOLLICULITIS | 1,945 |
| HYPERTENSION | 1,915 |
| DUODENAL ULCER PERFORATION | 1,905 |
Reactions in Hospitalization Reports
Hospitalization mid-share (20,636, 13.1%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PAIN | 4,036 |
| FATIGUE | 3,589 |
| ARTHRALGIA | 3,559 |
| MALAISE | 3,362 |
| PSORIATIC ARTHROPATHY | 3,086 |
| DIARRHOEA | 2,916 |
| RASH | 2,913 |
| JOINT SWELLING | 2,850 |
| HEADACHE | 2,835 |
| PYREXIA | 2,757 |
| VOMITING | 2,727 |
| RHEUMATOID ARTHRITIS | 2,723 |
| PNEUMONIA | 2,622 |
| CONDITION AGGRAVATED | 2,618 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2,602 |
| SWELLING | 2,577 |
| NAUSEA | 2,559 |
| PERIPHERAL SWELLING | 2,526 |
How to read secukinumab FAERS figures (MEGA-CASE · DEATH-MARKED · HOSP-MID)
FAERS holds 157,236 voluntary reports linked to secukinumab (Cosentyx), 2012-2025. Death is listed on 7,752 (4.9%). Hospitalization appears on 20,636 (13.1%). Top co-reported indication: Psoriasis.
MEGA-CASE books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.
Read with secukinumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 155,147 FAERS cases (Δ 2,089 lighter vs secukinumab); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's MEGA-CASE · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 155,068 FAERS cases (Δ 2,168 lighter vs secukinumab); DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED vs this page's MEGA-CASE · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 150,998 FAERS cases (Δ 6,238 lighter vs secukinumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's MEGA-CASE · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 165,585 FAERS cases (Δ 8,349 heavier vs secukinumab); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's MEGA-CASE · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 57.2 pp vs secukinumab's DEATH-MARKED): CASELOAD · HOSP-MID.
secukinumab sits in MEGA-CASE; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.